Difamilast (Adquey) for Atopic Dermatitis
Difamilast (Adquey) for Atopic Dermatitis
November 23, 2026 (Issue: 1768)
The FDA has approved Adquey (Acrotech), a 1% ointment
formulation of the phosphodiesterase-4 (PDE4) inhibitor
difamilast, for topical treatment of mild to moderate atopic
dermatitis (AD) in patients ≥2 years old. Difamilast is the third
PDE4...more
- Crisaborole (Eucrisa) for atopic dermatitis. Med Lett Drugs Ther 2017; 59:34.
- Roflumilast cream (Zoryve) for atopic dermatitis. Med Lett Drugs Ther 2024; 66:150.
- Tapinarof cream (Vtama) for atopic dermatitis. Med Lett Drugs Ther 2025; 67:37.
- Ruxolitinib (Opzelura) for atopic dermatitis. Med Lett Drugs Ther 2022; 64:12.
- Drugs for atopic dermatitis. Med Lett Drugs Ther 2026; 68:33.
- L Wang et al. Effectiveness and safety of topical phosphodiesterase 4 inhibitors in children with mild-to-moderate atopic dermatitis: a systematic review and meta-analysis. J Int Med Res 2025; 53:3000605251333654. doi:10.1177/03000605251333654
- JM Hanifin et al. OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild to moderate atopic dermatitis (AD): a phase-II randomized, double-blind, placebo-controlled study. J Am Acad Dermatol 2016; 75:297. doi:10.1016/j.jaad.2016.04.001
- H Saeki et al. Difamilast ointment in adult patients with atopic dermatitis: a phase 3 randomized, double-blind, vehicle-controlled trial. J Am Acad Dermatol 2022; 86:607. doi:10.1016/j.jaad.2021.10.027
- H Saeki et al. Difamilast, a selective phosphodiesterase 4 inhibitor, ointment in paediatric patients with atopic dermatitis: a phase III randomized double-blind, vehicle-controlled trial. Br J Dermatol 2022; 186:40. doi:10.1111/bjd.20655
- H Saeki et al. Difamilast ointment in Japanese adult and pediatric patients with atopic dermatitis: a phase III, long-term, open-label study. Dermatol Ther (Heidelb) 2022; 12:1589. doi:10.1007/s13555-022-00751-9
- H Saeki et al. A phase 3, long-term, open-label study of difamilast ointment to evaluate efficacy and safety in Japanese infants with atopic dermatitis. Dermatol Ther (Heidelb) 2026; 16:339. doi:10.1007/s13555-025-01581-1
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to
The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App
- FREE online per issue CME/CE
Purchase this article:
Title: Difamilast (Adquey) for Atopic Dermatitis
Article code: 1768c
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
